Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.965 USD | -0.17% | -5.73% | +67.23% |
May. 14 | Taysha Gene Therapies Q1 Net Loss Narrows, Revenue Declines -- Shares Down After Hours | MT |
May. 14 | Transcript : Taysha Gene Therapies, Inc., Q1 2024 Earnings Call, May 14, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+67.23% | 555M | |
+62.29% | 62.59B | |
-2.46% | 41.18B | |
+44.42% | 40.29B | |
-8.29% | 27.9B | |
+12.48% | 26.21B | |
-21.78% | 19.09B | |
+5.19% | 13.08B | |
+25.03% | 12.26B | |
+28.08% | 12.05B |
- Stock Market
- Equities
- TSHA Stock
- News Taysha Gene Therapies, Inc.
- Canaccord Genuity Adjusts Price Target on Taysha Gene Therapies to $6 From $7, Maintains Buy Rating